Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP9853 + docetaxel
- Development stage
- Discontinued
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**ASP9853 + docetaxel** is a combination therapy investigated for advanced solid tumors. ASP9853 is a small molecule inhibitor of **inducible nitric oxide synthase (iNOS) dimerization**, leading to decreased nitric oxide (NO) production. Docetaxel is a taxane-class antineoplastic agent that inhibits microtubule depolymerization, disrupting cell division and inducing apoptosis. Preclinical studies demonstrated synergistic antitumor activity of ASP9853 with taxanes (docetaxel and paclitaxel) in xenograft cancer models. In a Phase I clinical trial, ASP9853 was administered orally daily in combination with intravenous docetaxel every three weeks in patients with advanced non-hematologic malignancies. The combination showed increased toxicity (notably neutropenia and leukopenia) compared to docetaxel alone, and did not result in improved clinical efficacy; the study was terminated early without determination of the maximum tolerated dose or recommended Phase II dose[1][3][7][9].
- Other names
- ASP9853 + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))NOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on ASP9853 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP9853 + docetaxel.